Recent Updates in PEACE-3 Trial Presented at ESMO 2024

Opinion
Video

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      3 experts are featured in this series.
      COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
      3 experts are featured in this series.
      Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
      Clinical Impact of COCOON: Advancing Dermatologic AE Management
      Clinical Impact of COCOON: Advancing Dermatologic AE Management
      Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
      Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
      Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
      Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
      Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
      Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
      1 expert is featured in this series.
      Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
      3 experts are featured in this series.
      Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
      3 experts are featured in this series.
      Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
      Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
      Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
      Related Content
      Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

      Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

      Jason M. Broderick
      April 22nd 2025
      Article

      The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive non–muscle-invasive bladder cancer.

      Read More

      FDA Grants Approval to Durvalumab in MIBC

      FDA Grants Approval to Durvalumab in MIBC

      Jordyn Sava
      March 28th 2025
      Article

      This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.

      Read More

      Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC

      Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC

      Jordyn Sava
      March 26th 2025
      Article

      Belzupacap sarotalocan showed rapid immune activation and a favorable safety profile as a treatment for non–muscle-invasive bladder cancer.

      Read More

      Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

      Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

      Jonah Feldman
      March 24th 2025
      Article

      A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

      Read More

      EAP Enhances Access to Cretostimogene Grenadenorepvec

      EAP Enhances Access to Cretostimogene Grenadenorepvec

      Hannah Clarke
      March 12th 2025
      Article

      An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

      Read More

      Expert Explores Trials in CIS-Refractory Bladder Cancer

      Expert Explores Trials in CIS-Refractory Bladder Cancer

      Jason M. Hafron, MD, CMO
      March 12th 2025
      Article

      Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

      Read More